Down More Than 20% In The Last Month, Is UnitedHealth Stock A Buy On The Dip?

UnitedHealth (UNH) stock has declined over 20% in May and is down approximately 50% from its year-to-date high, prompting Deutsche Bank and KeyBanc to maintain bullish ratings, citing attractive valuations and expectations for headwinds to resolve by early 2026. Deutsche Bank has a "Buy" rating with a $362 target, while KeyBanc has a $400 target; the consensus rating is "Strong Buy" with a mean target of $392, indicating a potential upside of nearly 30%.

Analysis

UnitedHealth (UNH) has experienced a significant downturn, with its stock price declining over 20% in May and approximately 50% from its year-to-date high, driven by the suspension of its full-year guidance and accusations of improper practices involving payments to nursing homes to minimize hospitalizations. Despite these challenges, analysts from Deutsche Bank and KeyBanc present a contrarian bullish outlook. Deutsche Bank, rating UNH "Buy" with a $362 price target which implies 20% upside, emphasizes the stock's current trading multiple, which is significantly below its 10-year range, suggesting a compelling valuation opportunity even based on conservative 2025 trough earnings estimates. They also project up to 5% operating profit growth in the core managed care business as Medicare Advantage plans mature. KeyBanc echoes this optimism with a $400 price target, anticipating that many of the current headwinds will resolve by early 2026, creating an attractive investment setup. This positive sentiment is further supported by reported insider buying of UNH stock following the recent crash and a "Strong Buy" consensus rating from Wall Street, with a mean target price of $392 indicating nearly 30% potential upside for the latter half of 2025.

Key Decisions for Investors

• Investors might consider the current historically discounted valuation of UNH as a potential entry point, aligning with analyst views that even conservative earnings projections offer meaningful upside from current levels.
• Closely monitor developments regarding the suspended full-year guidance and the ongoing accusations, as the resolution of these headwinds, which KeyBanc anticipates by early 2026, is critical to the prevailing bullish analyst outlook.
• Weigh the positive signals, such as recent insider buying activity and the strong Wall Street consensus rating, against the inherent risks associated with the company's operational uncertainties and the significant recent stock price correction before making investment decisions.